help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Speel, E. J. M.
Right arrow Articles by Komminoth, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Speel, E. J. M.
Right arrow Articles by Komminoth, P.
(American Journal of Pathology. 1999;155:1787-1794.)
© 1999 American Society for Investigative Pathology


Short Communications

Genetic Differences in Endocrine Pancreatic Tumor Subtypes Detected by Comparative Genomic Hybridization

Ernst J. M. Speel*, Jan Richter{dagger}, Holger Moch{dagger}, Carole Egenter{dagger}, Parvin Saremaslani*, Katrin Rütimann*, Jianming Zhao*, André Barghorn*, Jürgen Roth{ddagger}, Philipp U. Heitz* and Paul Komminoth*{ddagger}

From the Department of Pathology,*
and Division of Cell and Molecular Pathology,{ddagger}
University of Zürich, Zürich; and the Institute of Pathology,{dagger}
University of Basel, Basel, Switzerland

The molecular pathogenesis as well as histogenesis of endocrine pancreatic tumors (EPTs) is not well understood, and the clinical behavior of EPTs is difficult to predict using current morphological criteria. Thus, more accurate markers of risk and better understanding of tumor initiation and progression are needed to allow a precise classification of EPTs. We have studied 44 benign and malignant EPTs by comparative genomic hybridization to correlate the overall number of genetic alterations with clinical and histopathological parameters and to identify chromosomal regions which might harbor genes involved in EPT pathogenesis and progression. Aberrations were found in 36 EPTs, and chromosomal losses (mean, 5.3) were slightly more frequent than gains (mean, 4.6). The most frequent losses involved Y (45% of male EPTs), 6q (39%), 11q (36%), 3p, 3q, 11p (each 30%), 6p (27%), and 10q and Xq (each 25%), whereas most common gains included 7q (43%), 17q (41%), 5q and 14q (each 32%), 7p, 9q, 17p, 20q (each 27%), and 12q and Xp (each 25%). A correlation was found between the total number of genetic changes per tumor and both tumor size and disease stage. In particular, losses of 3p and 6 and gains of 14q and Xq were found to be associated with metastatic disease. Furthermore, characteristic patterns of genetic changes were found in the various EPT subtypes, eg, 6q loss in malignant insulinomas, indicating that these groups might evolve along genetically different pathways. The highlighted genetic aberrations, including the newly found involvement of 6q losses and sex chromosome alterations, should stimulate the further analysis of these chromosomal regions, which may lead to the discovery of novel genes important in the tumorigenesis and evolution of EPTs.





This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
E.-M. Duerr, Y. Mizukami, A. Ng, R. J Xavier, H. Kikuchi, V. Deshpande, A. L Warshaw, J. Glickman, M. H Kulke, and D. C Chung
Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis
Endocr. Relat. Cancer, March 1, 2008; 15(1): 243 - 256.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
Y M H Jonkers, S M H Claessen, A Perren, A M Schmitt, L J Hofland, W de Herder, R R de Krijger, A A J Verhofstad, A R Hermus, J A Kummer, et al.
DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients
Endocr. Relat. Cancer, September 1, 2007; 14(3): 769 - 779.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
Y. Nagano, D. H. Kim, L. Zhang, J. A White, J. C Yao, S. R Hamilton, and A. Rashid
Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis
Endocr. Relat. Cancer, June 1, 2007; 14(2): 483 - 492.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
Y M H Jonkers, S M H Claessen, A Perren, S Schmid, P Komminoth, A A Verhofstad, L J Hofland, R R de Krijger, P J Slootweg, F C S Ramaekers, et al.
Chromosomal instability predicts metastatic disease in patients with insulinomas
Endocr. Relat. Cancer, June 1, 2005; 12(2): 435 - 447.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A Perren, S Schmid, T Locher, P Saremaslani, C Bonvin, P U Heitz, and P Komminoth
BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors
Endocr. Relat. Cancer, December 1, 2004; 11(4): 855 - 860.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Furlan, R. Cerutti, S. Uccella, S. La Rosa, E. Rigoli, A. Genasetti, and C. Capella
Different Molecular Profiles Characterize Well-Differentiated Endocrine Tumors and Poorly Differentiated Endocrine Carcinomas of the Gastroenteropancreatic Tract
Clin. Cancer Res., February 1, 2004; 10(3): 947 - 957.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
E. D. Rosen, R. N. Kulkarni, P. Sarraf, U. Ozcan, T. Okada, C.-H. Hsu, D. Eisenman, M. A. Magnuson, F. J. Gonzalez, C. R. Kahn, et al.
Targeted Elimination of Peroxisome Proliferator-Activated Receptor {gamma} in {beta} Cells Leads to Abnormalities in Islet Mass without Compromising Glucose Homeostasis
Mol. Cell. Biol., October 15, 2003; 23(20): 7222 - 7229.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-J. Chen, A. Vortmeyer, Z. Zhuang, S. Huang, and R. T. Jensen
Loss of Heterozygosity of Chromosome 1q in Gastrinomas: Occurrence and Prognostic Significance
Cancer Res., February 15, 2003; 63(4): 817 - 823.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. U. Goebel, M. Iwamoto, M. Raffeld, F. Gibril, W. Hou, J. Serrano, and R. T. Jensen
HER-2/neu Expression and Gene Amplification in Gastrinomas: Correlations with Tumor Biology, Growth, and Aggressiveness
Cancer Res., July 1, 2002; 62(13): 3702 - 3710.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. J. M. Speel, A. F. Scheidweiler, J. Zhao, C. Matter, P. Saremaslani, J. Roth, P. U. Heitz, and P. Komminoth
Genetic Evidence for Early Divergence of Small Functioning and Nonfunctioning Endocrine Pancreatic Tumors: Gain of 9Q34 Is an Early Event in Insulinomas
Cancer Res., July 1, 2001; 61(13): 5186 - 5192.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Barghorn, E. J. M. Speel, B. Farspour, P. Saremaslani, S. Schmid, A. Perren, J. Roth, P. U. Heitz, and P. Komminoth
Putative Tumor Suppressor Loci at 6q22 and 6q23-q24 Are Involved in the Malignant Progression of Sporadic Endocrine Pancreatic Tumors
Am. J. Pathol., June 1, 2001; 158(6): 1903 - 1911.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
H Tonnies, M R Toliat, C Ramel, U F Pape, H Neitzel, W Berger, and B Wiedenmann
Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation
Gut, April 1, 2001; 48(4): 536 - 541.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
O. Hessman, B. Skogseid, G. Westin, and G. Åkerström
Multiple Allelic Deletions and Intratumoral Genetic Heterogeneity in MEN1 Pancreatic Tumors
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1355 - 1361.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
G. Rigaud, E. Missiaglia, P. S. Moore, G. Zamboni, M. Falconi, G. Talamini, A. Pesci, A. Baron, D. Lissandrini, G. Rindi, et al.
High Resolution Allelotype of Nonfunctional Pancreatic Endocrine Tumors: Identification of Two Molecular Subgroups with Clinical Implications
Cancer Res., January 1, 2001; 61(1): 285 - 292.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
F. Yu, R. T. Jensen, I. A. Lubensky, E. H. Mahlamaki, Y.-L. Zheng, A. M. Herr, and L. J. Ferrin
Survey of Genetic Alterations in Gastrinomas
Cancer Res., October 1, 2000; 60(19): 5536 - 5542.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J. A. Lees, P. U. Heitz, and C. Eng
Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells
Am. J. Pathol., October 1, 2000; 157(4): 1097 - 1103.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Dannenberg, E. J.M. Speel, J. Zhao, P. Saremaslani, E. van der Harst, J. Roth, P. U. Heitz, H. J. Bonjer, W. N.M. Dinjens, W. J. Mooi, et al.
Losses of Chromosomes 1p and 3q Are Early Genetic Events in the Development of Sporadic Pheochromocytomas
Am. J. Pathol., August 1, 2000; 157(2): 353 - 359.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society for Investigative Pathology.